Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | PHASE3 | ACTIVE NOT_RECRUITING | 46 | — | — | Jan 22, 2024 | Apr 1, 2027 | Aug 6, 2025 | 1 | United States |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | PHASE3 | ACTIVE NOT_RECRUITING | 293 | — | — | Apr 1, 2022 | Jun 1, 2027 | Aug 7, 2025 | 184 | United States, Australia +18 |
Median hematocrit
Number of phlebotomies
Response is defined as absence of phlebotomy eligibility.
| Arm | Type | Description |
|---|---|---|
| Open-label rusfertide | EXPERIMENTAL | Open-label rusfertide |
| Rusfertide | EXPERIMENTAL | Rusfertide (32 Weeks) - Rusfertide (124 Weeks Open-label) |
| Placebo | EXPERIMENTAL | Placebo (32 Weeks) - Rusfertide (124 Weeks Open-label) |
| Name | Type | Description |
|---|---|---|
| Open-label rusfertide | DRUG | subcutaneous rusfertide |
| Placebo | DRUG | Placebo |
| Rusfertide | DRUG | Experimental drug |
Inclusion Criteria: * Subject who has completed at least 12 months of dosing with rusfertide and successfully completed the end of treatment visit of a previous Phase 2 study of rusfertide. * Subject understands the study procedures, is willing and able to adhere to study requirements and agrees to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide, Open-label rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE2 | sapablursen |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | — | Undisclosed |